Â鶹×îгöÆ·

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation - Â鶹×îгöÆ· - Outstanding Awards (Details)

v3.22.0.1
Stock-Based Compensation - Â鶹×îгöÆ· - Outstanding Awards (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Additional disclosures Ìý Ìý Ìý
Total unrecognized compensation cost related to unvested equity awards $ 49 Ìý Ìý
Weighted average period of recognition related to unvested equity awards (in years) 1 year 7 months 6 days Ìý Ìý
Options, exercises in period, total intrinsic value $ 144 $ 8 $ 163
Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, vested in period, fair value $ 13 $ 45 $ 17
Â鶹×îгöÆ· SiriusXM Group Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Common stock reserved for issuance 7,400 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Common Class A Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Common Class B Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Series C Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at beginning of period 10,870 Ìý Ìý
Granted 323 Ìý Ìý
Exercised (3,823) Ìý Ìý
Forfeited/Cancelled (1) Ìý Ìý
Outstanding at end of period 7,369 10,870 Ìý
Exercisable at end of period 5,213 Ìý Ìý
WAEP Ìý Ìý Ìý
Outstanding at beginning of period $ 34.96 Ìý Ìý
Granted 45.79 Ìý Ìý
Exercised 28.48 Ìý Ìý
Forfeited/Cancelled 42.62 Ìý Ìý
Outstanding at end of period 38.79 $ 34.96 Ìý
Exercisable at end of period $ 36.39 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average remaining life, outstanding 3 years 4 months 24 days Ìý Ìý
Weighted average remaining life, exercisable 2 years 7 months 6 days Ìý Ìý
Aggregate intrinsic value, outstanding $ 89 Ìý Ìý
Aggregate intrinsic value, exercisable $ 75 Ìý Ìý
Â鶹×îгöÆ· SiriusXM Group | Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, nonvested, number 73 Ìý Ìý
Restricted stock weighted average grant-date fair value $ 41.81 Ìý Ìý
Formula One Group Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Common stock reserved for issuance 9,100 Ìý Ìý
Formula One Group | Common Class A Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 1 Ìý Ìý
WAEP Ìý Ìý Ìý
Exercised $ 12.63 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average period of recognition related to unvested equity awards (in years) 1 year Ìý Ìý
Formula One Group | Common Class B Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Formula One Group | Series C Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at beginning of period 10,391 Ìý Ìý
Granted 773 Ìý Ìý
Exercised (2,050) Ìý Ìý
Outstanding at end of period 9,114 10,391 Ìý
Exercisable at end of period 7,507 Ìý Ìý
WAEP Ìý Ìý Ìý
Outstanding at beginning of period $ 31.78 Ìý Ìý
Granted 46.40 Ìý Ìý
Exercised 25.71 Ìý Ìý
Outstanding at end of period 34.38 $ 31.78 Ìý
Exercisable at end of period $ 32.42 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average remaining life, outstanding 4 years 2 months 12 days Ìý Ìý
Weighted average remaining life, exercisable 4 years Ìý Ìý
Aggregate intrinsic value, outstanding $ 263 Ìý Ìý
Aggregate intrinsic value, exercisable $ 231 Ìý Ìý
Formula One Group | Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, nonvested, number 138 Ìý Ìý
Restricted stock weighted average grant-date fair value $ 46.42 Ìý Ìý
Braves Group Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Common stock reserved for issuance 3,100 Ìý Ìý
Braves Group | Common Class A Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 1 Ìý Ìý
WAEP Ìý Ìý Ìý
Exercised $ 12.35 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average period of recognition related to unvested equity awards (in years) 1 year Ìý Ìý
Braves Group | Common Class B Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at end of period 0 Ìý Ìý
Braves Group | Series C Ìý Ìý Ìý
Number of options Ìý Ìý Ìý
Outstanding at beginning of period 3,475 Ìý Ìý
Granted 23 Ìý Ìý
Exercised (373) Ìý Ìý
Outstanding at end of period 3,125 3,475 Ìý
Exercisable at end of period 649 Ìý Ìý
WAEP Ìý Ìý Ìý
Outstanding at beginning of period $ 24.81 Ìý Ìý
Granted 30.17 Ìý Ìý
Exercised 16.39 Ìý Ìý
Outstanding at end of period 25.86 $ 24.81 Ìý
Exercisable at end of period $ 20.58 Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Weighted average remaining life, outstanding 5 years 1 month 6 days Ìý Ìý
Weighted average remaining life, exercisable 2 years 7 months 6 days Ìý Ìý
Aggregate intrinsic value, outstanding $ 7 Ìý Ìý
Aggregate intrinsic value, exercisable $ 5 Ìý Ìý
Braves Group | Restricted Stock and Restricted Stock Units Ìý Ìý Ìý
Additional disclosures Ìý Ìý Ìý
Equity instruments other than options, nonvested, number 219 Ìý Ìý
Restricted stock weighted average grant-date fair value $ 28.62 Ìý Ìý